Literature DB >> 7097255

Influenza virus replication in human alveolar macrophages.

B C Rodgers, C A Mims.   

Abstract

Studies with animal models suggest that alveolar macrophages may be important cells in some respiratory virus infections, but little is known about the role of these cells in virus infections in man. In this study human alveolar macrophages were obtained by fibreoptic bronchoscopy and infected in vitro with a variety of influenza viruses. After infection with the NWS strain of influenza virus the haemagglutinin and nucleoprotein viral antigens were demonstrated in greater than 90% of cells at 24 h by immunofluorescence with specific antisera. There was no cytopathic effect at this time, and no virus release was detected by plaque assay of culture fluids on MDCK cells. Alveolar macrophages were also infected with a human vaccine strain (H1N1) of influenza virus and with two recent isolates (H1N1 and H3N2). In each case viral nucleoprotein antigen was produced in 10-20% of the cells by 24 h postincubation, but there was no release of infectious virus. There was no cytopathic effect and the phagocytosis of IgG-coated latex beads was unimpaired 24 h after in vitro infection.

Entities:  

Mesh:

Year:  1982        PMID: 7097255     DOI: 10.1002/jmv.1890090304

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  19 in total

1.  Rhinovirus replication in human macrophages induces NF-kappaB-dependent tumor necrosis factor alpha production.

Authors:  Vasile Laza-Stanca; Luminita A Stanciu; Simon D Message; Michael R Edwards; James E Gern; Sebastian L Johnston
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Strain-dependent effects of PB1-F2 of triple-reassortant H3N2 influenza viruses in swine.

Authors:  Lindomar Pena; Amy L Vincent; Crystal L Loving; Jamie N Henningson; Kelly M Lager; Weizhong Li; Daniel R Perez
Journal:  J Gen Virol       Date:  2012-07-18       Impact factor: 3.891

3.  N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN.

Authors:  Sarah L Londrigan; Stuart G Turville; Michelle D Tate; Yi-Mo Deng; Andrew G Brooks; Patrick C Reading
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

4.  Cytokine release from human peripheral blood leucocytes incubated with endotoxin with and without prior infection with influenza virus: relevance to the sudden infant death syndrome.

Authors:  J B Lundemose; H Smith; C Sweet
Journal:  Int J Exp Pathol       Date:  1993-06       Impact factor: 1.925

5.  Human Alveolar Macrophages May Not Be Susceptible to Direct Infection by a Human Influenza Virus.

Authors:  David B Ettensohn; Mark W Frampton; Joan E Nichols; Norbert J Roberts
Journal:  J Infect Dis       Date:  2016-09-06       Impact factor: 5.226

6.  Reovirus infection in rat lungs as a model to study the pathogenesis of viral pneumonia.

Authors:  M J Morin; A Warner; B N Fields
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Development of interleukin 6 and tumor necrosis factor alpha activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus.

Authors:  K Matsuda; H Tsutsumi; Y Okamoto; C Chiba
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

Review 8.  Influenza virus replication in macrophages: balancing protection and pathogenesis.

Authors:  Troy D Cline; Donald Beck; Elizabeth Bianchini
Journal:  J Gen Virol       Date:  2017-09-08       Impact factor: 3.891

9.  Further studies of the reasons for the lack of alveolar infection during influenza in ferrets.

Authors:  C Sweet; R A Bird; A J Howie; H A Overton; D M Coates; H Smith
Journal:  Br J Exp Pathol       Date:  1985-04

10.  Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

Authors:  Lisa M Alleva; Charles Cai; Ian A Clark
Journal:  Evid Based Complement Alternat Med       Date:  2009-09-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.